Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia

Potentially first new class of antibiotics in Phase III development against Gram-negative pathogens in 50 years

March 27, 2018
Polyphor Ltd

March 27th, 2018 - Polyphor today announced the enrollment of the first patient in its PRISM-MDR European Phase III clinical trial for murepavadin (POL7080) for the treatment of ventilator-associated bacterial pneumonia (VABP) due to Pseudomonas aeruginosa.

Press Release available here: